Integrating Immunizations Into Practice

Number 558

ABSTRACT: Given demonstrated vaccine efficacy, safety, and the large potential for prevention of many infectious diseases among adults, newborns, and pregnant women, obstetrician–gynecologists should...

Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women

Number 557

ABSTRACT: Initial evaluation of the patient with acute abnormal uterine bleeding should include a prompt assessment for signs of hypovolemia and potential hemodynamic instability. After initial asses...

Postmenopausal Estrogen Therapy: Route of Administration and Risk of Venous Thromboembolism

Number 556

ABSTRACT: The development of menopausal symptoms and related disorders, which lead women to seek prescriptions for postmenopausal estrogen therapy and hormone therapy, is a common reason for a patien...

Over-the-Counter Access to Oral Contraceptives

Number 544

ABSTRACT: Unintended pregnancy remains a major public health problem in the United States. Access and cost issues are common reasons why women either do not use contraception or have gaps in use. A p...

Access to Emergency Contraception

Number 542

ABSTRACT: Emergency contraception includes contraceptive methods used to prevent pregnancy in the first few days after unprotected intercourse, sexual assault, or contraceptive failure. Although the ...

Risk of Venous Thromboembolism Among Users of Drospirenone-Containing Oral Contraceptive Pills

Number 540

ABSTRACT: Although the risk of venous thromboembolism is increased among oral contraceptive users compared with nonusers who are not pregnant and not taking hormones, and some data have suggested tha...

Compounded Bioidentical Menopausal Hormone Therapy

Number 532

(Replaces No. 387, November 2007 and No. 322, November 2005)

ABSTRACT: Although improvement in long-term health is no longer an indication for menopausal hormone therapy, evidence supporting fewer adverse events in younger women, combined with its high overall...

Long-Acting Reversible Contraception -- Implants and Intrauterine Devices

Number 121

(Replaces Practice Bulletin Number 59, January 2005)

Intrauterine devices and contraceptive implants, also called long-acting reversible contraceptives (LARCs), are the most effective reversible contraceptives. The major advantage of LARCs compared wit...

Misoprostol for Postabortion Care

Number 427

ABSTRACT: The World Health Organization estimates that 67,000 women, mostly in developing countries, die each year from untreated or inadequately treated abortion complications. Postabortion care, a ...

Aromatase Inhibitors in Gynecologic Practice

Number 412

(Reaffirmed 2012)

ABSTRACT: Aromatase inhibitors appear to be effective as an adjuvant treatment for early-stage and late-stage breast cancer. Their role in chemoprevention of breast cancer in high-risk patients remai...

Intraperitoneal Chemotherapy for Ovarian Cancer

Number 396

(Reaffirmed 2010 )

ABSTRACT: Postoperative intravenous (IV) chemotherapy for advanced stage ovarian cancer has been the standard treatment. Recent studies have found significant survival advantages with the use of adju...

Brand Versus Generic Oral Contraceptives

Number 375

(Reaffirmed 2010)

ABSTRACT:The U.S. Food and Drug Administration considers generic and brand name oral contraceptive (OC) products clinically equivalent and interchangeable. The American College of Obstetricians and G...

Tamoxifen and Uterine Cancer

Number 336

(Reaffirmed 2008, Replaces No. 232, April 2000)

ABSTRACT: Tamoxifen may be associated with endometrial proliferation, hyperplasia, polyp formation, invasive carcinoma, and uterine sarcoma. Any symptoms of endometrial hyperplasia or cancer reported...